Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (P13-04)

Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)

This is a Group Sequential Test multicenter, randomized, double blind, placebo controlled phase II proof of concept trial with parallel groups to evaluate the efficacy and the safety of BP1.4979 15mg BID compared to placebo in RLS patients during 2 weeks double blind treatment.

Study Overview

• Status: Terminated
• Conditions: Restless Legs Syndrome
• Intervention / Treatment: Drug: BP 1.4979; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • Clinical Neurophysiology Department - Hôpital Pellegrin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males or females > or = to 18 years
• 18 kg/m2 ≤ BMI ≤ 35 kg/m2

• Diagnosis of idiopathic RLS based on medical history and the presence of the 5 RLS diagnostic criteria and a normal clinical examination

  1. An urge to move the legs usually but not always accompanied by, or felt to be caused by, uncomfortable and unpleasant sensations in the legs.
  2. The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting.
  3. The urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
  4. The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day.
  5. The occurrence of the above features is not solely accounted for as symptoms primary to another medical or a behavioral condition.
• The condition is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder.
• RLS severity score > or = to 21/40 and RLS occurring at least 3 times per week for 'de novo' patients or after RLS treatment wash-out.
• Periodic Limb Movements during Sleep index > 15 for 'de novo' patients or after RLS treatment wash out.
• Not taking or accepting to discontinue drug therapy or medication for RLS, antipsychotic medication, antidepressant including Selective Serotonin Reuptake Inhibitors (SSRIs) prescribed for at least 5 half-lives prior to randomization (e.g. fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram, venlafaxine, milnacipran, duloxetine) and/or any other psychotropic medication benzodiazepine and/or anticonvulsivants (gabapentine, pregabaline) prescribed to relief RLS, for at least 5 half-lives prior to randomization and/or opiates.
• Females of child-bearing potential must use a medically accepted effective method of birth control, agree to continue this method for the duration of the study and be negative to serum pregnancy test performed at the screening visit. Females should not be breast-feeding. Males accept to use child conception prevention method for the whole duration of the study
• In the opinion of the investigator, the subject must have adequate support to comply with the entire study requirements as described in the protocol (e.g. transportation to and from trial site, self-rating scales, drug compliance, scheduled visits, etc).
• Patient must have voluntarily expressed willingness to participate in this study, understand protocol procedures and have signed and dated an informed consent prior to beginning any protocol required procedures.

Exclusion Criteria:

• Any significant psychiatric illness (schizophrenia, bipolar disorder, severe depression, dementia, obsessive compulsive disorder...) or mood disorder, assessed by the Beck Depression Inventory (BDI) (exclusion if > or = to 16 and/ or item G ≠ 0).
• Abnormal neurological examination, history or presence of chronic pain other than that associated with RLS. History of epilepsy or serious head injury. History of peripheral neuropathy.
• Clinically significant sleep apnea (Apnea Hypopnea Index >15), narcolepsy, parasomnia as an adult, circadian rhythm disorder, or secondary causes of RLS (e.g chronic renal failure/hemodialysis).
• Other active clinically significant illness, including unstable cardiovascular, or neoplasic pathology which could interfere with the study conduct or counter-indicate the study treatments, place the subject at risk during the trial or interfere with study assessments or compromise the study participation.
• Subject with a known history of long QTc syndrome (e.g. syncope or arrhythmia) or presenting any significant serious abnormality of the ECG (e.g. recent myocardial infarction), or QTcB interval strictly higher than 450 ms.
• Subject with moderate hepatic impairment (transaminases > 1.5 ULN) or with renal impairment (creatinine clearance < 90 mL/min) , or with any other significant abnormality in the physical examination or clinical laboratory results (e.g positive laboratory test for Hepatitis B surface antigen (HBsAg), or anti-HIV 1/2 or anti- HCV antibodies).
• Iron deficiency (ferritin < 50 µg/l).
• Known hypersensitivity to the tested treatment including active substance and excipients.
• Use of drugs likely to influence sleep architecture or motor manifestations during sleep prior to randomization without an appropriate wash-out period. These include neuroleptics, L-dopa, dopamine agonists, hypnotics, sedatives, anxiolytics, antidepressants, anticonvulsants, psychostimulant medications, steroids in the evening, barbiturates, benzodiazepine treatment and opiates to relief RLS.
• Patient taking any prescription drug containing amphetamines.
• Recent history (≤ 1 year) of alcohol or drug abuse, or current evidence of substance dependence or abuse as defined by DSM-IV criteria (Gebauer L, LaBrie R et al. 2010).
• Regular consumption of large amounts of xanthine-containing substances (i.e more than 5 cups of coffee or equivalent amounts of xanthine-containing substance per day).
• Patient participating in another study and the use of any investigational therapy within the 30 days prior to the entry in this study.
• Patient without any medical care insurance.
• Pregnant woman or a pregnancy detected with a positive serum pregnancy test performed at the screening visit or lactating female.
• Male patient who wants to conceive a child for the whole duration of the study.
• Patient under guardianship who cannot provide consent on his own.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Matching placebo tablet	Drug: Placebo; Double blind versus placebo
Experimental: BP 1.4979; 15 mg tablet BID	Drug: BP 1.4979; Double blind versus placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Periodic Limb Movements per hour of Sleep (PLMS index)	Measure of the difference from baseline (Randomization) to the end of the double blind treatment period in Periodic Limb Movements per hour of Sleep (PLMS index) measured with PolySomnoGraphy (PSG)	2 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IRLSRS (International Restless Legs Syndrome Rating Scale)	Difference in IRLSRS score measured at randomization and end double blind study.treatment period. IRLSRS is ranging from 0 (no symptoms) to 40 (very severe symptoms)	2 weeks
Periodic Limb Movement during Wakefulness (PLMW)	Difference in PLMW measured at randomization and end double blind study treatment period. The PLMW will be measured during a Suggested Immobilization Test (1-hour test) to evaluate the limb movements during wakefulness.	2 weeks
Safety assessed by AEs collection	Safety and tolerability of BP 1.4979 as assessed by AEs collection	Up to 3 weeks

Collaborators and Investigators

• Sponsor: Bioprojet
• Investigators: Principal Investigator: Imad Ghorayeb, MD, Hopital Pellegrin

Study record dates

Study Major Dates

• Study Start (Actual): February 6, 2018
• Primary Completion (Actual): April 29, 2020
• Study Completion (Actual): April 29, 2020

Study Registration Dates

• First Submitted: November 9, 2017
• First Submitted That Met QC Criteria: November 14, 2017
• First Posted (Actual): November 17, 2017

Study Record Updates

• Last Update Posted (Actual): July 30, 2020
• Last Update Submitted That Met QC Criteria: July 28, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Neurologic Manifestations; Neurobehavioral Manifestations; Disease; Dyskinesias; Psychomotor Disorders; Parasomnias; Syndrome; Psychomotor Agitation; Restless Legs Syndrome
• Other Study ID Numbers: P13-04 / BP 1.4979; 2013-004884-30 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No